Westerdijk, Kim <br/><br/>
Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.  [electronic resource] 

 -  British journal of clinical pharmacology  02 2020 
 - 258-273 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1365-2125 
<br/><br/><label>Standard No.: </label>10.1111/bcp.14185  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--adverse effects<br/>Drug Monitoring<br/>Humans<br/>Imatinib Mesylate<br/>Indazoles<br/>Protein Kinase Inhibitors--adverse effects<br/>Pyrimidines<br/>Sulfonamides<br/>Sunitinib